Affimed (NASDAQ:AFMD – Get Rating) is scheduled to be releasing its earnings data before the market opens on Wednesday, June 1st. Analysts expect Affimed to post earnings of ($0.18) per share for the quarter.
Affimed (NASDAQ:AFMD – Get Rating) last issued its earnings results on Thursday, March 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). The firm had revenue of $11.82 million during the quarter, compared to analysts’ expectations of $10.30 million. Affimed had a negative net margin of 149.76% and a negative return on equity of 40.66%. During the same quarter in the prior year, the company earned ($0.20) EPS. On average, analysts expect Affimed to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of NASDAQ AFMD opened at $3.12 on Wednesday. The business’s 50 day moving average price is $3.97 and its 200 day moving average price is $4.73. The firm has a market cap of $385.07 million, a P/E ratio of -5.47 and a beta of 2.49. Affimed has a 52 week low of $2.88 and a 52 week high of $9.23. The company has a quick ratio of 3.19, a current ratio of 3.20 and a debt-to-equity ratio of 0.13.
A number of brokerages recently commented on AFMD. StockNews.com lowered Affimed from a “hold” rating to a “sell” rating in a research report on Monday, March 28th. Cantor Fitzgerald began coverage on Affimed in a research report on Wednesday, February 23rd. They issued an “overweight” rating and a $12.00 price objective on the stock. Piper Sandler began coverage on Affimed in a research report on Wednesday, March 30th. They issued an “overweight” rating and a $7.00 price objective on the stock. Finally, Zacks Investment Research upgraded Affimed from a “sell” rating to a “hold” rating in a research report on Tuesday, April 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Affimed has a consensus rating of “Buy” and an average price target of $10.17.
Affimed Company Profile (Get Rating)
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma.
- Get a free copy of the StockNews.com research report on Affimed (AFMD)
- Two Retailers, One To Buy And One To Avoid
- It’s Time to Buy into Planet Fitness Stock
- Indie Semiconductor Stock is Putting in a Bottom
- Investors Can Get 5%-Plus Dividend Yields on These 3 Buys
- 3 Defensive Consumer Stocks Worth Shopping For
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.